Company registration number 14453265 (England and Wales)
GEETA PHARMA LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2024
PAGES FOR FILING WITH REGISTRAR
GEETA PHARMA LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 5
Accountants' report
6
Detailed Profit and Loss
GEETA PHARMA LIMITED
BALANCE SHEET
AS AT 30 SEPTEMBER 2024
30 September 2024
- 1 -
2024
2023
Notes
£
£
£
£
Fixed assets
Investments
3
237,243
-
0
Current assets
Debtors
4
370,418
-
0
Cash at bank and in hand
2,558
2
372,976
2
Creditors: amounts falling due within one year
5
(214,798)
-
0
Net current assets
158,178
2
Total assets less current liabilities
395,421
2
Creditors: amounts falling due after more than one year
6
(384,885)
-
0
Net assets
10,536
2
Capital and reserves
Called up share capital
7
100
2
Profit and loss reserves
10,436
-
0
Total equity
10,536
2

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 30 September 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

GEETA PHARMA LIMITED
BALANCE SHEET (CONTINUED)
AS AT 30 SEPTEMBER 2024
30 September 2024
- 2 -
The financial statements were approved by the board of directors and authorised for issue on 7 April 2025 and are signed on its behalf by:
Mr J Gurung
Director
Company registration number 14453265 (England and Wales)
GEETA PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2024
- 3 -
1
Accounting policies
Company information

Geeta Pharma Limited is a private company limited by shares incorporated in England and Wales. The registered office is 19 Crossmead Avenue, Greenford, UB6 9TY.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.2
Fixed asset investments

Interests in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.

A subsidiary is an entity controlled by the company. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

1.3

Related party exemption

The company has taken advantage of the exemption, under the terms of Financial Reporting Standard 102,' The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2024
2023
Number
Number
Total
2
2
3
Fixed asset investments
2024
2023
£
£
Shares in group undertakings and participating interests
237,243
-
0
GEETA PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2024
3
Fixed asset investments
(Continued)
- 4 -
Movements in fixed asset investments
Shares in subsidiaries
£
Cost or valuation
At 1 October 2023
-
Additions
237,243
At 30 September 2024
237,243
Carrying amount
At 30 September 2024
237,243
At 30 September 2023
-
4
Debtors
2024
2023
Amounts falling due within one year:
£
£
Amounts owed by group undertakings
370,418
-
0
5
Creditors: amounts falling due within one year
2024
2023
£
£
Bank loans
16,468
-
0
Other creditors
198,330
-
0
214,798
-
0
6
Creditors: amounts falling due after more than one year
2024
2023
Notes
£
£
Bank loans and overdrafts
384,885
-
0
GEETA PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2024
6
Creditors: amounts falling due after more than one year
(Continued)
- 5 -

The bank loans and overdrafts falling due less than 1 year and after more than 1 year are secured by a fixed and floating charge over the assets of the company.

 

The following assets held as security are charged to TSB Bank plc;

 

1. A Guarantee from Hayes End Healthcare Limited for a principal amount of £414,120 plus interest and other costs as detailed in the guarantee and in respect of your debts and liabilities to the Bank together with such other securities as the Bank may from time to time hold in respect of the debts and liabilities of the guarantor to the Bank supported by a legal charge from Hayes End Healthcare Limited over the Leasehold Building and Land at 1266 Uxbridge Road, Hayes, Middlesex, UB4 8JF.

 

2. A Guarantee from Mr J Gurung and Mrs K Gurung for a principal amount of £414,120 plus interest and other costs as detailed in the guarantee and in respect of your debts and liabilities to the Bank together with such other securities as the Bank may from time to time hold in respect of the debts and liabilities of the guarantor to the Bank.

 

3. An unlimited debenture from Geeta Pharma Ltd.

 

4. An unlimited debenture from Hayes End Healthcare Limited.

 

5. An assignment in security by Mr J Gurung and Mrs K Gurung of a life insurance policy for an amount not less than £414,120.

 

6. Cross company guarantee (OGSA) between Geeta Pharma Ltd & Hayes End Healthcare Limited.

 

7. Letter of Postponement of Director’s Loan by Mr J Gurung for £51,000

 

8. Letter of Postponement of Director’s Loan by Mrs K Gurung for £51,000

Amounts included above which fall due after five years are as follows:
Payable by instalments
305,168
-
7
Called up share capital
2024
2023
2024
2023
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of £1 each
100
2
100
2

During the year, the company issued 98 ordinary shares of £1 each at par value.

8
Directors' transactions

At the year end, the directors are owed £197,609. The loan attracts no interest and is repayable on demand.

GEETA PHARMA LIMITED
ACCOUNTANTS' REPORT TO THE BOARD OF DIRECTORS ON THE PREPARATION OF THE UNAUDITED STATUTORY FINANCIAL STATEMENTS OF GEETA PHARMA LIMITED FOR THE YEAR ENDED 30 SEPTEMBER 2024
- 6 -

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Geeta Pharma Limited for the year ended 30 September 2024 which comprise, the balance sheet and the related notes from the company’s accounting records and from information and explanations you have given us.

 

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed at https://www.icaew.com/regulation.

This report is made solely to the board of directors of Geeta Pharma Limited, as a body, in accordance with the terms of our engagement letter dated 18 March 2024. Our work has been undertaken solely to prepare for your approval the financial statements of Geeta Pharma Limited and state those matters that we have agreed to state to the board of directors of Geeta Pharma Limited, as a body, in this report in accordance with ICAEW Technical Release 07/16 AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Geeta Pharma Limited and its board of directors as a body, for our work or for this report.

It is your duty to ensure that Geeta Pharma Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and profit of Geeta Pharma Limited. You consider that Geeta Pharma Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of Geeta Pharma Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.

Aequitas Accountants Ltd
7 April 2025
Chartered Accountants
Elthorne Gate
64 High Street
Pinner
Middlesex
HA5 5QA
2024-09-302023-10-01falsefalsefalse07 April 2025CCH SoftwareCCH Accounts Production 2025.100No description of principal activityMrs K GurungMr J Gurung144532652023-10-012024-09-30144532652024-09-30144532652023-09-3014453265core:CurrentFinancialInstrumentscore:WithinOneYear2024-09-3014453265core:CurrentFinancialInstrumentscore:WithinOneYear2023-09-3014453265core:Non-currentFinancialInstrumentscore:AfterOneYear2024-09-3014453265core:Non-currentFinancialInstrumentscore:AfterOneYear2023-09-3014453265core:CurrentFinancialInstruments2024-09-3014453265core:CurrentFinancialInstruments2023-09-3014453265core:ShareCapital2024-09-3014453265core:ShareCapital2023-09-3014453265core:RetainedEarningsAccumulatedLosses2024-09-3014453265core:RetainedEarningsAccumulatedLosses2023-09-3014453265core:ShareCapitalOrdinaryShareClass12024-09-3014453265core:ShareCapitalOrdinaryShareClass12023-09-3014453265bus:Director22023-10-012024-09-30144532652022-11-012023-09-3014453265core:Non-currentFinancialInstruments2024-09-3014453265core:Non-currentFinancialInstruments2023-09-3014453265bus:OrdinaryShareClass12023-10-012024-09-3014453265bus:OrdinaryShareClass12024-09-3014453265bus:OrdinaryShareClass12023-09-3014453265bus:PrivateLimitedCompanyLtd2023-10-012024-09-3014453265bus:SmallCompaniesRegimeForAccounts2023-10-012024-09-3014453265bus:FRS1022023-10-012024-09-3014453265bus:AuditExemptWithAccountantsReport2023-10-012024-09-3014453265bus:Director12023-10-012024-09-3014453265bus:FullAccounts2023-10-012024-09-30xbrli:purexbrli:sharesiso4217:GBP